Cangen Biotechnologies

Cangen Biotechnologies, Inc. is a cancer-focused biotechnology company that develops and markets early detection diagnostic test products for cancer. The company specializes in molecular diagnostics for cancer. It also develops chemosensitivity technologies to improve the selection of cancer treatment options, as well as targeted drugs and biological cancer therapies, including vaccines. The company has collaborated with Olympus Corporation to develop a DNA-based hybrid diagnostic test for the early detection of lung cancer.